09.00 - 10.15
PRE-CONFERENCE SESSION | CLINICAL TRIALS
chairperson: prof. Krzysztof Giannopoulos, prof. Wojciech Jurczak
chairperson: prof. Krzysztof Giannopoulos, prof. Wojciech Jurczak
09.00 - 09.15
Clinical trials in Poland - opportunities and challenges | Rafał Staszewski, PhD [Deputy President for Research Funding at the Polish Medical Research Agency]
09.15 - 09.30
Challenges of the future: the quality of clinical research | Marta Halke-Markiewicz, Maciej Rewers
09.30 - 09.45
The role of local CROs in organizing and conducting research in Poland | Izabela Kozdraś-Urbanek, PhD
09.45 - 10.15
Discussion | How to increase the number of clinical research allocated in Poland?
10.30 - 10.40
Opening of the conference |
prof. Monika Długosz-Danecka, prof. Wojciech Jurczak, prof. Lidia Gil, prof. Iwona Hus
prof. Monika Długosz-Danecka, prof. Wojciech Jurczak, prof. Lidia Gil, prof. Iwona Hus
10.40 - 11.40
SCIENTIFIC SESSION I: Changing the standard of lymphoma treatment in Poland
chairpersons: prof. Ewa Lech-Marańda, prof. Aleksander Skotnicki, prof. Janusz Ryś
chairpersons: prof. Ewa Lech-Marańda, prof. Aleksander Skotnicki, prof. Janusz Ryś
10.40 - 10.55
New therapeutic programmes for lymphoma patients | prof. Ewa Lech-Marańda
10.55 - 11.10
Lenalidomide - the first effective immunomodulatory drug | prof. Dominik Dytfeld
11.10 – 11.25
Sponsored lecture 
History of biosimilar medicines: Rituximab biosimilars | prof. Wiesław W. Jędrzejczak
History of biosimilar medicines: Rituximab biosimilars | prof. Wiesław W. Jędrzejczak
11.25 - 11.40
Discussion
11.40 - 11.55
Coffee break
11.55 - 13.25
SCIENTIFIC SESSION II: CLL - How to find yourself in a new reality?
chairpersons: prof. Tadeusz Robak, prof. Wojciech Jurczak
chairpersons: prof. Tadeusz Robak, prof. Wojciech Jurczak
11.55 - 12.25
Treatment of CLL - from chlorambucil to targeted therapies | prof. Tadeusz Robak
12.25 - 12.40
What's new at iwCLL? | prof. Iwona Hus
12.40 - 01.10
Lecture patronaged by 
Three generations of BTK inhibitors | prof. Paolo Ghia
Three generations of BTK inhibitors | prof. Paolo Ghia
13.10 - 13.25
Discussion
13.25 - 13.40
Coffee break
13.40 - 14.50
SPONSORED DEBATE: CLL - chronic treatment or time-limited therapy?
chairpersons: prof. Iwona Hus, prof. Krzysztof Giannopoulos
chairpersons: prof. Iwona Hus, prof. Krzysztof Giannopoulos
13.40 - 13.50
Sponsored lecture by .png)
VenO only in 1L – a chance for patients to receive the shortest targeted therapy | prof. Iwona Hus
VenO only in 1L – a chance for patients to receive the shortest targeted therapy | prof. Iwona Hus
13.50 - 14.00
Sponsored lecture by 
CLL therapy - the perspective of a patient with high genetic risk features | prof. Krzysztof Giannopoulos
CLL therapy - the perspective of a patient with high genetic risk features | prof. Krzysztof Giannopoulos
14.00 - 14.10
Sponsored lecture by
The role and place of Zanubrutinib in the treatment of patients with chronic lymphocytic leukemia based on the results of the SEQUOIA and ALPPINE trials | prof. Wojciech Jurczak
The role and place of Zanubrutinib in the treatment of patients with chronic lymphocytic leukemia based on the results of the SEQUOIA and ALPPINE trials | prof. Wojciech Jurczak
14.10 – 14.20
Sponsored lecture by 
Synergy and effectiveness. New time-limited therapy ibrutinib + venetoclax | prof. Tadeusz Robak
Synergy and effectiveness. New time-limited therapy ibrutinib + venetoclax | prof. Tadeusz Robak
14.20 - 14.50
Sponsored debate: prof. Iwona Hus, prof. Tadeusz Robak, prof. Krzysztof Giannopoulos, prof. Bartosz Puła, prof. Wojciech Jurczak
14.50 - 15.25
Lunch
15.25 - 16.25
SCIENTIFIC SESSION III: Indolent lymphomas
chairperson: prof. Marcin Pasiarski, prof. Tomasz Wróbel
chairperson: prof. Marcin Pasiarski, prof. Tomasz Wróbel
15.25 - 15.40
Is immunochemotherapy still SOC in the 1st-line treatment of indolent lymphomas? The place of maintenance therapy in the COVID era | prof. Marcin Pasiarski
15.40 - 15.55
An alternative to immunochemotherapy in subsequent relapses of follicular lymphoma |
prof. Tomasz Wróbel
prof. Tomasz Wróbel
15.55 - 16.10
Lecture patronaged by
What’s new in MW? | prof. Bartosz Puła
What’s new in MW? | prof. Bartosz Puła
16.10 - 16.25
Discussion
16.25 - 16.40
Coffee break
16.40 – 17.55
SCIENTIFIC SESSION IV: MCL
chairpersons: prof. Jan Walewski, prof. Wojciech Jurczak
chairpersons: prof. Jan Walewski, prof. Wojciech Jurczak
16.40 - 16.55
IBTK in 1st line treatment of MCL | prof. Jan Walewski
16.55 - 17.10
The place of ASCT and alloSCT in the treatment of MCL | prof. Lidia Gil
17.10 - 17.40
The role of cell therapies in MCL | prof. Michael Wang
17.40 - 17.55
Discussion
17.55 - 18.10
Coffee break
18.10 - 19.10
SCIENTIFIC SESSION V: ALL
chairpersons: prof. Jan Styczyński, prof. Tomasz Szczepański
chairpersons: prof. Jan Styczyński, prof. Tomasz Szczepański
18.10 - 18.25
Personalisation of treatment based on genomics and minimal residual disease | prof. Tomasz Szczepański
18.25 - 18.40
ALL: differences between children and adults | prof. Jan Styczyński
18.40 - 18.55
ALL in adults | prof. Anna Czyż
18.55 - 19.10
Discussion
19.30
Dinner
09.00 - 10.00
SCIENTIFIC SESSION VI: CD30-positive lymphomas: Hodgkin lymphoma and anaplastic lymphoma
chairperson: prof. Jan Maciej Zaucha, prof. Monika Długosz-Danecka
chairperson: prof. Jan Maciej Zaucha, prof. Monika Długosz-Danecka
09.00 - 09.15
Can radiotherapy be omitted from the first-line treatment of HD? | prof. Jan Maciej Zaucha
09.15 - 09.30
Targeted chemotherapy in the treatment of CD30+ lymphomas | prof. Monika Długosz-Danecka
9.30 - 09.45
Immunotherapy in R/R HD | prof. Aleksandra Butrym
09.45 - 10.00
Discussion
10.00 - 10.15
Coffee break
10.15 - 12.00
SCIENTIFIC SESSION VII: Aggressive lymphomas
chairpersons: prof. Grzegorz Nowakowski, prof. Wojciech Jurczak
chairpersons: prof. Grzegorz Nowakowski, prof. Wojciech Jurczak
10.15 - 10.30
Is R-CHOP still the SOC for the treatment of 1st line aggressive lymphomas? | prof. Wojciech Jurczak
10.30 - 10.45
Immunotherapy of R/R DLBCL | dr Anna Dąbrowska-Iwanicka
10.45 - 11.00
Place of targeted therapies in relapsed/refractory agressive lymphomas | prof. Monika Długosz-Danecka
11.00 - 11.30
Bispecific antibodies in the treatment of aggressive lymphomas | prof. Grzegorz Nowakowski
11.30 - 11.45
Sponsored lecture by
Efficacy and safety of epcoritamab in the treatment of R/R DLBCL | prof. Wojciech Jurczak
Efficacy and safety of epcoritamab in the treatment of R/R DLBCL | prof. Wojciech Jurczak
11.45 - 12.00
Discussion
12.00 - 12.15
Coffee break
12.15 - 13.15
SCIENTIFIC SESSION VIII: Aggressive lymphomas - the twilight of the ASCT era
chairpersons: prof. Lidia Gil, prof. Bogusław Machaliński
chairpersons: prof. Lidia Gil, prof. Bogusław Machaliński
12.15 - 12.30
ASCT vs CAR-T in the treatment of first relapsed aggressive lymphoma | prof. Grzegorz Basak
12.30 - 12.45
Cell therapies in the treatment of R/R DLBCL | prof. Lidia Gil
12.45 - 13.00
University CAR-T therapies | prof. Bogusław Machaliński
13.00 - 13.15
Discussion
13.15 - 13.30
Coffee break
13.30 - 14.30
SCIENTIFIC SESSION IX: Multiple myeloma
chairpersons: prof. Krzysztof Giannopoulos, prof. Dominik Dytfeld
chairpersons: prof. Krzysztof Giannopoulos, prof. Dominik Dytfeld
13.30 - 13.45
Myeloma - one disease of many targeted therapies | prof. Dominik Dytfeld
13.45 - 14.00
What is the optimum time for ASCT? | prof. Krzysztof Giannopoulos
14.00 - 14.15
Progress in myeloma supportive treatment | prof. Artur Jurczyszyn
14.15 - 14.30
Discussion
14.30
Closing of the conference
prof. Monika Długosz-Danecka, prof. Wojciech Jurczak, prof. Lidia Gil, prof. Iwona Hus
prof. Monika Długosz-Danecka, prof. Wojciech Jurczak, prof. Lidia Gil, prof. Iwona Hus
14.45
Lunch